Media headlines about Peregrine Pharmaceuticals (NASDAQ:PPHM) have trended very positive on Saturday, according to Alpha One Sentiment Analysis. The research group, a subsidiary of Accern, rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Alpha One ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Peregrine Pharmaceuticals earned a news impact score of 0.52 on Alpha One’s scale. Alpha One also gave news headlines about the biopharmaceutical company an impact score of 88 out of 100, meaning that recent media coverage is very likely to have an impact on the company’s share price in the immediate future.
These are some of the headlines that may have effected AlphaOne Sentiment’s scoring:
- Zooming in on the Numbers for Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) – Jonesboro Recorder (jonesbororecorder.com)
- Sentiment Change Report: Peregrine Pharmaceuticals Inc (NASDAQ:PPHM) – Weekly Register (weeklyregister.com)
- Peregrine Pharmaceuticals Series E Convertible Preferred Stock Ex-Dividend Reminder – Nasdaq (nasdaq.com)
- Peregrine Pharmaceuticals Inc (PPHM) Moving -1.08% in Session – Financial News Review (finnewsreview.com)
- A Technical Perspective On Peregrine Pharmaceuticals, Inc. (PPHM), Ashford Hospitality Trust, Inc. (AHT) – AllStockNews (allstocknews.com)
Several research firms recently commented on PPHM. ValuEngine cut Peregrine Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, June 9th. Zacks Investment Research cut Peregrine Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, May 3rd. Finally, Noble Financial reissued a “buy” rating on shares of Peregrine Pharmaceuticals in a research note on Thursday, April 6th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $0.94.
Peregrine Pharmaceuticals (NASDAQ PPHM) traded up 1.4674% on Friday, reaching $0.5601. The company had a trading volume of 1,253,739 shares. Peregrine Pharmaceuticals has a 12 month low of $0.28 and a 12 month high of $0.77. The firm has a 50-day moving average of $0.58 and a 200-day moving average of $0.49. The stock’s market capitalization is $166.75 million.
ILLEGAL ACTIVITY WARNING: “Peregrine Pharmaceuticals (PPHM) Earning Very Positive News Coverage, Report Shows” was first published by WKRB News and is the property of of WKRB News. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.wkrb13.com/markets/2230598/peregrine-pharmaceuticals-pphm-earning-very-positive-news-coverage-report-shows.html.
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2230598/peregrine-pharmaceuticals-pphm-earning-very-positive-news-coverage-report-shows.html
Receive News & Ratings for Peregrine Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Peregrine Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.